618966Vedic Lifesciences Pvt. Ltd, Mumbai, India.
Nanjing Nutrabuilding Bio-tech Co., Ltd, Nanjing, China.
Int J Toxicol. 2022 Aug;41(4):329-346. doi: 10.1177/10915818221094487. Epub 2022 May 13.
L-3-Aminoisobutyric acid (L-BAIBA) is an endogenous compound in human metabolism when thymine and valine undergo catabolism. L-BAIBA represents one of the two isomers of BAIBA in biological systems. BAIBA has been shown to reduce body fat percentage via an increase in fatty acid oxidation and a decrease in hepatic lipogenesis. However, no toxicological effects of L-BAIBA in animals or humans have been established. The present study was designed to evaluate the safety and toxic potentials of this compound, where L-BAIBA was administered orally to Sprague Dawley rats at 100, 300, and 900 mg/kg/day for 90 days. No treatment-related adverse effects were observed in any of the treatment groups. Based on the results, the No-Observed-Adverse-Effect Level (NOAEL) of L-BAIBA was 900 mg/kg/day.
L-3-氨基异丁酸（L-BAIBA）是人类代谢中胸腺嘧啶和缬氨酸分解时的内源性化合物。L-BAIBA 代表生物体系中两种 BAIBA 异构体之一。BAIBA 已被证明通过增加脂肪酸氧化和减少肝脂肪生成来降低体脂肪百分比。然而，尚未在动物或人类中确立 L-BAIBA 的毒理学效应。本研究旨在评估该化合物的安全性和毒性潜力，其中 L-BAIBA 以 100、300 和 900mg/kg/天的剂量经口给予 Sprague Dawley 大鼠 90 天。在任何治疗组中均未观察到与治疗相关的不良反应。基于这些结果，L-BAIBA 的无观察到不良效应水平（NOAEL）为 900mg/kg/天。
